BR112015019064A8 - uso de uma composição compreendendo nanopartículas compreendendo paclitaxel e uma albumina para o tratamento de melanoma e kit - Google Patents
uso de uma composição compreendendo nanopartículas compreendendo paclitaxel e uma albumina para o tratamento de melanoma e kit Download PDFInfo
- Publication number
- BR112015019064A8 BR112015019064A8 BR112015019064A BR112015019064A BR112015019064A8 BR 112015019064 A8 BR112015019064 A8 BR 112015019064A8 BR 112015019064 A BR112015019064 A BR 112015019064A BR 112015019064 A BR112015019064 A BR 112015019064A BR 112015019064 A8 BR112015019064 A8 BR 112015019064A8
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- composition
- nanoparticles
- melanoma
- paclitaxel
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
Abstract
abstract provided herein are methods for the treatment of melanoma comprising administration of a composition comprising nanoparticles comprising taxane and a carrier protein. __________ tradução do resumo resumo patente de invenção: "métodos de tratamento de melanoma". são fornecidas aqui métodos para o tratamento de mela-noma, compreendendo a administração de uma composição compre-endendo nanopartículas compreendendo taxano e uma proteína veículo.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361763391P | 2013-02-11 | 2013-02-11 | |
US13/791,841 US9149455B2 (en) | 2012-11-09 | 2013-03-08 | Methods of treating melanoma |
PCT/US2013/072877 WO2014123612A1 (en) | 2013-02-11 | 2013-12-03 | Methods of treating melanoma |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112015019064A2 BR112015019064A2 (pt) | 2017-07-18 |
BR112015019064A8 true BR112015019064A8 (pt) | 2019-11-12 |
Family
ID=51300036
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015019064A BR112015019064A8 (pt) | 2013-02-11 | 2013-12-03 | uso de uma composição compreendendo nanopartículas compreendendo paclitaxel e uma albumina para o tratamento de melanoma e kit |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP2953622B1 (pt) |
JP (3) | JP6388880B2 (pt) |
KR (1) | KR102148551B1 (pt) |
CN (2) | CN109200031A (pt) |
BR (1) | BR112015019064A8 (pt) |
CA (1) | CA2900668A1 (pt) |
ES (1) | ES2872328T3 (pt) |
HK (1) | HK1218506A1 (pt) |
IL (1) | IL240388B (pt) |
MX (1) | MX2015010312A (pt) |
NZ (1) | NZ630239A (pt) |
WO (1) | WO2014123612A1 (pt) |
ZA (1) | ZA201505956B (pt) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011123393A1 (en) | 2010-03-29 | 2011-10-06 | Abraxis Bioscience, Llc | Methods of enhancing drug delivery and effectiveness of therapeutic agents |
JP5926724B2 (ja) | 2010-03-29 | 2016-05-25 | アブラクシス バイオサイエンス, エルエルシー | がんを処置する方法 |
US9427477B2 (en) | 2011-05-09 | 2016-08-30 | Mayo Foundation For Medical Education And Research | Cancer treatments |
ME03532B (me) | 2011-12-14 | 2020-04-20 | Abraxis Bioscience Llc | Upotreba polimernih ekscipijenata za liofilizaciju ili zamrzavanje parтikula |
CA2917407C (en) | 2012-10-01 | 2023-03-14 | Mayo Foundation For Medical Education And Research | Complexes containing albumin-containing nanoparticles and antibodies to treat cancer |
US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
NZ630392A (en) | 2013-03-12 | 2016-10-28 | Abraxis Bioscience Llc | Methods of treating lung cancer |
WO2014151853A1 (en) | 2013-03-14 | 2014-09-25 | Abraxis Bioscience, Llc | Methods of treating bladder cancer |
WO2015095842A2 (en) * | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers |
MX2016016617A (es) | 2014-06-16 | 2017-03-23 | Mayo Foundation | Tratamiento de mielomas. |
DK3204413T3 (da) * | 2014-10-06 | 2019-12-09 | Mayo Found Medical Education & Res | Bærerantistofsammensætninger og fremgangsmåder til fremstilling og anvendelse heraf |
US9446148B2 (en) | 2014-10-06 | 2016-09-20 | Mayo Foundation For Medical Education And Research | Carrier-antibody compositions and methods of making and using the same |
US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
ES2897991T3 (es) | 2015-06-29 | 2022-03-03 | Abraxis Bioscience Llc | Nanopartículas que comprenden sirolimus y una albúmina para uso en tratamiento de tumores de células epitelioides |
TW201707725A (zh) | 2015-08-18 | 2017-03-01 | 美國馬友醫藥教育研究基金會 | 載體-抗體組合物及其製造及使用方法 |
EP3337823A4 (en) * | 2015-08-18 | 2019-05-08 | Mayo Foundation for Medical Education and Research | SUPPORTING BIN COMPOSITIONS AND METHOD FOR THE PRODUCTION AND USE THEREOF |
TW201713360A (en) * | 2015-10-06 | 2017-04-16 | Mayo Foundation | Methods of treating cancer using compositions of antibodies and carrier proteins |
EP3399861A4 (en) | 2016-01-07 | 2019-08-07 | Mayo Foundation for Medical Education and Research | INTERFERON CANCER TREATMENT METHODS |
WO2017139698A1 (en) | 2016-02-12 | 2017-08-17 | Mayo Foundation For Medical Education And Research | Hematologic cancer treatments |
CA3018340A1 (en) | 2016-03-21 | 2017-09-28 | Mayo Foundation For Medical Education And Research | Methods for improving the therapeutic index for a chemotherapeutic drug |
CA3018341A1 (en) | 2016-03-21 | 2017-09-28 | Mayo Foundation For Medical Education And Research | Methods for reducing toxicity of a chemotherapeutic drug |
US10618969B2 (en) | 2016-04-06 | 2020-04-14 | Mayo Foundation For Medical Education And Research | Carrier-binding agent compositions and methods of making and using the same |
KR20190053203A (ko) | 2016-09-01 | 2019-05-17 | 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 | T-세포 암을 표적화하는 방법 및 조성물 |
ES2937291T3 (es) * | 2016-09-01 | 2023-03-27 | Mayo Found Medical Education & Res | Composiciones de agentes que se unen al transportador PD-L1 y métodos de uso de las mismas para tratar cánceres |
AU2017324335A1 (en) | 2016-09-06 | 2019-03-28 | Mayo Foundation For Medical Education And Research | Methods of treating PD-L1 expressing cancer |
MX2019002564A (es) | 2016-09-06 | 2019-09-18 | Mayo Found Medical Education & Res | Composiciones de agente de unión de albúmina-paclitaxel y métodos de uso y elaboración de las mismas. |
WO2018048815A1 (en) | 2016-09-06 | 2018-03-15 | Nantibodyfc, Llc | Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins |
RU2020110399A (ru) | 2017-10-03 | 2021-11-09 | Крититек, Инк. | Местная доставка противоопухолевых частиц в комбинации с системной доставкой иммунотерапевтических агентов для лечения рака |
EP3768268A4 (en) | 2018-03-20 | 2022-02-23 | Abraxis BioScience, LLC | METHOD OF TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS BY ADMINISTRATION OF NANOPARTICLES OF AN MTOR INHIBITOR AND AN ALBUMINE |
JP2022553426A (ja) | 2019-10-28 | 2022-12-22 | アブラクシス バイオサイエンス, エルエルシー | アルブミンおよびラパマイシンの医薬組成物 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
US5916596A (en) | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
TR200502189T1 (tr) | 2002-12-09 | 2007-01-22 | American Bioscience, Inc. | Kompozisyonlar ve farmakolojik etken maddelerin aktarımı için yöntemler. |
US8735394B2 (en) * | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
US20070166388A1 (en) * | 2005-02-18 | 2007-07-19 | Desai Neil P | Combinations and modes of administration of therapeutic agents and combination therapy |
EP3248600B8 (en) * | 2005-02-18 | 2020-06-24 | Abraxis BioScience, LLC | Combinations and modes of administration of therapeutic agents and combination therapy |
ES2719093T3 (es) | 2005-08-31 | 2019-07-08 | Abraxis Bioscience Llc | Composiciones de fármacos poco solubles en agua con mayor estabilidad y métodos para su preparación |
WO2007139930A2 (en) * | 2006-05-26 | 2007-12-06 | Bayer Healthcare Llc | Drug combinations with substituted diaryl ureas for the treatment of cancer |
CA2686736A1 (en) | 2007-05-03 | 2008-11-13 | Abraxis Bioscience, Llc | Nanoparticle compositions comprising rapamycin for treating pulmonary hypertension |
EP2367425B1 (en) * | 2008-12-11 | 2018-02-28 | Abraxis BioScience, LLC | Combination therapy including a taxane and a further therapeutic agent |
EP2625525A4 (en) * | 2010-10-08 | 2014-04-02 | Abraxis Bioscience Llc | SPARC MICRO ENVIRONMENT SIGNATURE, PLASMA SPARC AND LDH AS PROGNOSTIC BIOMARKERS IN THE TREATMENT OF CANCER |
-
2013
- 2013-12-03 CA CA2900668A patent/CA2900668A1/en not_active Abandoned
- 2013-12-03 WO PCT/US2013/072877 patent/WO2014123612A1/en active Application Filing
- 2013-12-03 CN CN201811025229.5A patent/CN109200031A/zh active Pending
- 2013-12-03 CN CN201380075292.9A patent/CN105120859B/zh active Active
- 2013-12-03 EP EP13874757.1A patent/EP2953622B1/en active Active
- 2013-12-03 ES ES13874757T patent/ES2872328T3/es active Active
- 2013-12-03 NZ NZ630239A patent/NZ630239A/en unknown
- 2013-12-03 BR BR112015019064A patent/BR112015019064A8/pt not_active Application Discontinuation
- 2013-12-03 JP JP2015556938A patent/JP6388880B2/ja active Active
- 2013-12-03 KR KR1020157024822A patent/KR102148551B1/ko active IP Right Grant
- 2013-12-03 MX MX2015010312A patent/MX2015010312A/es active IP Right Grant
-
2015
- 2015-08-06 IL IL240388A patent/IL240388B/en active IP Right Grant
- 2015-08-18 ZA ZA2015/05956A patent/ZA201505956B/en unknown
-
2016
- 2016-06-06 HK HK16106468.2A patent/HK1218506A1/zh unknown
-
2017
- 2017-11-07 JP JP2017214523A patent/JP6470381B2/ja active Active
-
2019
- 2019-01-17 JP JP2019006038A patent/JP2019056014A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
BR112015019064A2 (pt) | 2017-07-18 |
ZA201505956B (en) | 2016-11-30 |
IL240388B (en) | 2020-07-30 |
CA2900668A1 (en) | 2014-08-14 |
HK1218506A1 (zh) | 2017-02-24 |
EP2953622A4 (en) | 2016-09-21 |
KR20150119177A (ko) | 2015-10-23 |
CN105120859A (zh) | 2015-12-02 |
ES2872328T3 (es) | 2021-11-02 |
KR102148551B1 (ko) | 2020-08-26 |
EP2953622A1 (en) | 2015-12-16 |
JP2019056014A (ja) | 2019-04-11 |
JP2016513097A (ja) | 2016-05-12 |
WO2014123612A1 (en) | 2014-08-14 |
IL240388A0 (en) | 2015-09-24 |
MX2015010312A (es) | 2015-11-18 |
JP6470381B2 (ja) | 2019-02-13 |
JP6388880B2 (ja) | 2018-09-12 |
CN109200031A (zh) | 2019-01-15 |
JP2018016660A (ja) | 2018-02-01 |
EP2953622B1 (en) | 2021-03-24 |
NZ630239A (en) | 2017-08-25 |
CN105120859B (zh) | 2018-10-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015019064A8 (pt) | uso de uma composição compreendendo nanopartículas compreendendo paclitaxel e uma albumina para o tratamento de melanoma e kit | |
BR112015016681A8 (pt) | uso de nanopartículas compreendendo paclitaxel e uma albumina, kit, medicamento, composição e forma de dosagem unitária para tratamento de câncer pancreático | |
CY1121907T1 (el) | Συζευγματα antidll3-antiσωmatoς-pbd και χρησεις αυτων | |
CY1124436T1 (el) | Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια | |
CL2015000942A1 (es) | Compuestos de benceno sustituido. | |
BR112015026006A2 (pt) | métodos para o tratamento de câncer com o uso de terapia de combinação com inibidor de cinase tor | |
CY1125205T1 (el) | Φαρμακευτικες συνθεσεις δραστικων απο θεραπευτικη αποψη ενωσεων | |
EA201890146A1 (ru) | СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ | |
CL2016000468A1 (es) | Conjugados anti-dll3 (ligando3 tipo delta) manipulados y métodos de uso. | |
CL2015002472A1 (es) | Como inhibidores de mutant idh-yl-oxazolidin-2-onas 3-pirimidin-4. | |
PH12016500575A1 (en) | Inhibitors of bruton`s tyrosine kinase | |
CL2015000829A1 (es) | Inhibidores de histona desmetilasas | |
CL2016000866A1 (es) | Forma salina de hidrocloruro para la inhibición de ezh2 | |
MX2019001517A (es) | Complejos de nanopartículas de albúmina modificada con anticuerpos para el tratamiento del cáncer. | |
BR112015022047A8 (pt) | uso de uma composição compreendendo nanopartículas contendo um fármaco da família limo e uma albumina | |
EA201791516A1 (ru) | Способы комбинированного лечения злокачественных опухолей | |
BR112016002287A2 (pt) | compostos terapeuticamente ativos e seus métodos de uso | |
CL2015002767A1 (es) | Compuestos terapéuticos y composiciones | |
BR112015020389A2 (pt) | compostos carbazol úteis como inibidores de bromodomínio | |
BR112015026247A2 (pt) | métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor | |
BR112015026297A2 (pt) | terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer | |
MX2015010185A (es) | Composicion para uso cosmetico adecuada para producir un efecto de pigmentacion sobre el cabello. | |
MX2015011783A (es) | Metodos para tratar tumores solidos pediatricos. | |
BR112015020139A2 (pt) | compostos terapêuticos e usos dos mesmos | |
CL2015002897A1 (es) | Inhibidores de bace1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA. |
|
B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021 |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |